Three Biggest Japanese Drug Makers To Be Hit By Patent Losses
This article was originally published in PharmAsia News
The biggest Japanese drug makers face major decisions this year as some of their leading drugs edge closer to losing patent protection
You may also be interested in...
A new European Commission guidance document explains the regulatory basics and much- altered emergency market entry criteria for new entrants to devices sector amid the COVID-19 crisis.
The race is now on to get formal adoption of European Commission proposal postponing the MDR by one year and allowing more devices on the market more quickly. But potential hurdles are in the way as experts advise caution.